Article

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms

2022-03-15

Abstract excerpt

<title>Abstract</title> <p>Objective Aromatase inhibitors (AI) are commonly used to treat hormone receptor positive (HR+) breast cancer. AI-induced musculoskeletal syndrome (AIMSS) is a common toxicity that causes AI treatment discontinuation. The objective of this genome-wide association study (GWAS) was to identify genetic variants associated with discontinuation of AI therapy due to AIMSS and attempt to repli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: df4684cb-3a8e-5952-9928-9a8d2f3d511f
DOI: 10.21203/rs.3.rs-1315678/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptomsDOI 10.21203/rs.3.rs-1315678/v1Read

A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms: Results from ECOG-ACRIN E1Z11.Semantic proximity Read

Genetic associations with toxicity-related discontinuation of aromatase inhibitor therapy for breast cancer.Semantic proximity Read

Genetic determinants of aromatase inhibitor-related arthralgia: the B-ABLE cohort study.Semantic proximity Read

Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.Semantic proximity Read

Attempted replication of SNPs in RANKL and OPG with musculoskeletal adverse events during aromatase inhibitor treatment for breast cancer.Semantic proximity Read

Clinical and genetic risk factors for aromatase inhibitor-associated arthralgia in breast cancer survivors.Semantic proximity Read

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.Semantic proximity Read

Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.Semantic proximity Read

Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy in breast cancer patients.Semantic proximity Read

Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.Semantic proximity Read

Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse eventsSemantic proximity Read

Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic lociSemantic proximity Read